Fasting and Cancer
Fasting has become one of the most actively discussed nutritional approaches in cancer research. The interest is not simply because fasting reduces food intake, but because temporary changes in nutrient availability can influence several biological pathways involved in cancer biology.
During fasting, the body changes how it uses glucose, fat, and ketones and alters hormonal signals such as insulin and insulin-like growth factor-1 (IGF-1). These changes can influence pathways involved in cell growth, energy production, stress responses, inflammation, and immune activity.
Researchers are therefore investigating whether carefully timed fasting or fasting-mimicking diets could make certain cancer treatments more effective or alter the tumor environment.
Importantly, however, the strength of evidence differs considerably between laboratory experiments, animal studies, and human clinical trials. Many of the most exciting findings have come from preclinical research, while human evidence is still emerging.
Fasting should therefore be understood as a promising research area rather than an established treatment for cancer.
What Does “Fasting” Mean in Cancer Research?
The word “fasting” can be misleading because cancer research uses several different approaches under this broad term.
Some studies investigate short-term fasting, where participants consume little or no food for a limited period around cancer treatment. Other research examines intermittent fasting, time-restricted eating, periodic fasting, calorie restriction, or fasting-mimicking diets (FMDs).
An FMD is specifically designed to provide a small amount of food while producing some of the metabolic changes associated with fasting.
These approaches are not interchangeable. For example, avoiding food overnight for 12–16 hours produces a different physiological response from fasting for two or three days. Likewise, a carefully formulated low-calorie FMD is not identical to a water-only fast.
The duration, nutritional composition, timing relative to treatment, cancer type, and patient’s nutritional condition can all influence the outcome.
Therefore, results from one fasting protocol cannot automatically be applied to another.
Why Did Scientists Become Interested in Fasting?
The scientific interest in fasting partly comes from the unusual metabolism of cancer cells. Many cancer cells alter their energy-producing pathways to support rapid growth and division.
One well-known example is increased glucose consumption and glycolysis, a phenomenon associated with the Warburg effect.
However, cancer metabolism is much more complicated than simply “cancer cells eat sugar.” Tumors can use several nutrients and can adapt their metabolism depending on oxygen availability, nutrient supply, genetics, and the surrounding tumor microenvironment.
Fasting changes the systemic metabolic environment by lowering insulin and altering nutrient availability while increasing the use of stored fat and ketone bodies.
Researchers are investigating whether these changes create additional stress for certain cancer cells.
An important hypothesis is that healthy cells may temporarily shift into a protective, maintenance-oriented state during nutrient scarcity, whereas some cancer cells may remain committed to growth.
This difference could potentially create an opportunity to make certain treatments more selective.
The “Metabolic Switch” During Fasting
When food intake stops for a sufficient period, the body gradually transitions from using recently consumed nutrients toward stored energy.
Initially, the liver uses stored glycogen to help maintain blood glucose. As glycogen availability decreases, the body increasingly mobilizes stored fat, and the liver produces ketone bodies from fatty acids.
At the same time, insulin concentrations generally decline and other nutrient-sensing pathways change.
These are normal physiological adaptations that help humans survive periods when food is unavailable.
Researchers are interested in whether this temporary metabolic transition can also influence tumor behavior.
A tumor exposed to a changing nutrient and hormonal environment may experience different levels of metabolic stress depending on its genetic and metabolic characteristics.
Importantly, fasting does not completely remove glucose from the body or literally “starve” a tumor. The body continues to regulate blood glucose because glucose is essential for certain tissues.
The scientific question is therefore whether the overall metabolic shift can alter tumor vulnerability rather than whether fasting simply deprives cancer cells of food.
Fasting, Glucose, Insulin, and IGF-1
Insulin and IGF-1 are particularly important areas of investigation because they are involved in signaling pathways that regulate growth, metabolism, protein synthesis, and cell survival.
When a person fasts, insulin levels generally fall, and circulating IGF-1 can also decrease depending on the duration and nutritional state.
These hormonal changes can influence signaling pathways such as PI3K–AKT–mTOR, which are involved in cellular growth and metabolism.
In experimental cancer models, reducing these growth-promoting signals can sometimes slow tumor growth or increase sensitivity to treatment.
However, it is important not to oversimplify this finding. Lower insulin or IGF-1 does not automatically mean that a tumor will stop growing.
Cancer cells can activate alternative pathways and adapt to metabolic changes. Different cancers also have different metabolic requirements.
Therefore, researchers are investigating whether metabolic interventions could be useful for particular cancer types or molecular subgroups rather than assuming that the same approach will work for every patient.
Autophagy: The Cellular Recycling System
Autophagy is another biological process frequently discussed in relation to fasting.
The term describes a cellular recycling mechanism in which damaged proteins, organelles, and other cellular components are broken down and their building blocks can be reused.
Nutrient scarcity is one of the conditions that can stimulate autophagy because cells attempt to conserve resources and maintain essential functions.
This has led to popular descriptions of fasting as a way to “clean” or “detox” cells, but the scientific reality is more complicated.
Autophagy is not simply a cellular garbage disposal that automatically removes cancer.
In normal cells, it can help maintain cellular quality, while in some established tumors, increased autophagy can help cancer cells survive metabolic stress, oxygen deprivation, or treatment.
This means that autophagy can potentially have different effects at different stages of cancer development.
Researchers are therefore studying how fasting-induced autophagy interacts with specific cancer treatments rather than assuming that increasing autophagy is always beneficial.
Fasting and Chemotherapy: Why Is This Being Studied?
One of the most interesting hypotheses is that temporary fasting may alter how healthy and cancer cells respond to chemotherapy.
Chemotherapy targets rapidly dividing or otherwise vulnerable cancer cells, but it can also affect healthy tissues.
Preclinical experiments have suggested that temporary nutrient restriction can cause normal cells to reduce growth-related activity and activate protective stress responses.
Some cancer cells, because of persistent oncogenic signaling, may not make the same protective metabolic adjustment.
Researchers have proposed that this could create a temporary difference in stress tolerance between normal and malignant cells.
This concept is sometimes described as differential stress resistance.
Other research suggests that metabolic restriction may sometimes increase tumor sensitivity to treatment, referred to as differential stress sensitization.
These mechanisms are scientifically compelling, but a mechanism demonstrated in cells or mice does not automatically translate into a clinical benefit in humans.
Clinical trials are necessary to determine whether these changes actually improve treatment response, reduce toxicity, or affect long-term outcomes.
What Have Animal Studies Shown?
Animal experiments have provided some of the strongest evidence supporting further investigation of fasting in oncology.
In different mouse models, short-term fasting or fasting-mimicking diets have been associated with changes in tumor growth, chemotherapy response, metabolic signaling, oxidative stress, and immune activity.
Some studies have reported that fasting combined with anticancer therapy produced stronger tumor responses than treatment alone.
Other experiments have suggested that fasting-mimicking diets can alter immune-cell activity within the tumor microenvironment.
These findings are important because they show that dietary state can potentially interact with cancer treatment at several biological levels.
However, animal models have important limitations. Laboratory mice often have controlled diets, controlled environments, and specific tumor models that do not reproduce the full complexity of human cancers.
Human patients may have multiple medical conditions, medications, nutritional deficiencies, prior treatments, or significant muscle loss.
Therefore, animal studies provide a mechanistic foundation for clinical research but cannot establish that fasting improves cancer outcomes in people.
What About Human Clinical Research?
Human clinical research is currently much smaller and more heterogeneous than the preclinical literature.
Some early studies indicate that selected cancer patients can follow carefully designed fasting or fasting-mimicking protocols around treatment, particularly when nutritional status is monitored.
Researchers have observed metabolic changes such as reductions in insulin and IGF-1, changes in glucose metabolism, and alterations in inflammatory or immune markers.
Some studies have also reported potentially favorable changes in tumor response.
However, these studies often involve relatively small numbers of patients and different fasting protocols.
A 2025 systematic review examining intermittent fasting during chemotherapy or targeted therapy identified only nine eligible studies involving 354 patients, with many participants having breast cancer.
The review found that intermittent fasting appeared feasible in the populations studied and produced some consistent metabolic changes, but it did not establish a clear improvement in cancer outcomes or treatment-related toxicity.
These findings illustrate the current state of the field: biologically encouraging, clinically interesting, but not yet definitive.
The DIRECT Trial: An Important Human Example
The DIRECT trial is one of the better-known clinical studies examining a fasting-mimicking diet during chemotherapy.
The phase II trial involved 131 women with HER2-negative stage II–III breast cancer receiving neoadjuvant chemotherapy.
Participants assigned to the intervention followed a five-day fasting-mimicking diet around chemotherapy cycles.
The researchers reported that the intervention was feasible and investigated whether it could influence treatment response and chemotherapy-associated effects.
Some analyses suggested potentially favorable radiological and pathological responses, while other outcomes did not show a definitive clinical advantage.
Importantly, this study was not designed to establish that fasting improves long-term survival or prevents recurrence.
It also illustrates the importance of interpreting individual clinical trials within the wider evidence base.
A positive signal in a relatively limited trial can justify further investigation without being sufficient to establish a new standard of care.
Larger randomized trials with long-term follow-up are needed to determine whether these early findings translate into meaningful patient benefits.
A More Recent Randomized Breast Cancer Study
A 2024 randomized controlled study evaluated a fasting-mimicking diet in 44 patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy.
Participants followed the dietary intervention for several days before and during chemotherapy cycles.
Researchers reported changes in metabolic markers including glucose, insulin, and IGF-1, as well as differences in certain inflammatory and blood-cell measurements.
The study also reported potentially favorable differences in radiological and pathological treatment responses and fewer severe toxicities in some analyses.
These results are encouraging because they provide human evidence that a structured nutritional intervention can influence measurable biological processes during cancer treatment.
Nevertheless, the study was small, and small trials can produce results that later fail to appear in larger studies.
In addition, treatment response measured during the initial treatment period is not the same as demonstrating improved long-term survival.
Consequently, the study strengthens the rationale for further clinical research but does not establish fasting as a universal cancer treatment.
Another Human Study: Fasting and the Immune System
Researchers have also examined whether fasting-mimicking diets can influence the immune system.
In a clinical study involving 101 patients, a cyclic five-day fasting-mimicking diet was investigated alongside standard anticancer treatments.
The researchers observed metabolic changes, including reductions in glucose and growth-factor concentrations, together with changes in immune-cell populations and immune-related signals.
This is particularly interesting because modern cancer treatment increasingly includes immunotherapy and other approaches that depend on the patient’s immune system.
A dietary intervention that changes immune-cell metabolism could theoretically influence the tumor microenvironment or the ability of immune cells to respond to cancer.
However, immune biomarkers are intermediate outcomes. A change in the number or activity of a particular immune-cell population does not necessarily mean that a patient will live longer or experience better tumor control.
Future trials need to determine whether these biological changes translate into clinically meaningful improvements.
What Do Systematic Reviews Say?
Systematic reviews are particularly useful because individual studies can produce apparently impressive results that do not always remain consistent when more evidence becomes available.
A 2022 systematic review identified only eight clinical studies involving 379 patients examining fasting during cancer treatment.
The studies differed considerably in fasting duration, cancer type, treatment regimen, and outcome measurements.
The authors concluded that the evidence was insufficient to establish meaningful clinical benefits and highlighted concerns about weight loss and nutritional status.
A later 2023 systematic review and meta-analysis similarly found no statistically significant reduction in chemotherapy-related adverse events associated with therapeutic fasting compared with non-fasting approaches.
These reviews do not prove that fasting has no potential value. Instead, they show that the current human evidence is not yet strong enough to make broad clinical claims.
The distinction is important: an intervention can have a plausible mechanism and encouraging early findings while still lacking sufficient evidence to become standard medical practice.
Why Is the Human Evidence Difficult to Interpret?
One major problem is that there is no single standardized definition of therapeutic fasting in oncology.
One clinical trial might use a 24-hour fast, another may use several days of calorie restriction, while another uses a standardized fasting-mimicking diet.
The timing can also differ. Some interventions begin before chemotherapy, some continue through the treatment day, and others extend for several days afterward.
These differences can change the biological response.
Cancer type also matters. Breast cancer, lung cancer, colorectal cancer, pancreatic cancer, and blood cancers have different molecular characteristics and treatment strategies.
Even patients with the same cancer type may have substantially different tumor biology.
Furthermore, factors such as age, body composition, baseline nutrition, diabetes, medication use, physical activity, and previous treatment can influence how an individual responds.
These variables make it difficult to apply a single fasting recommendation to all cancer patients.
The Tumor Is Not One Uniform Mass
A tumor is not simply a collection of identical cancer cells. It is a complex ecosystem containing genetically and metabolically diverse cancer-cell populations together with immune cells, fibroblasts, blood vessels, extracellular matrix, and signaling molecules.
This environment is called the tumor microenvironment.
Different cancer cells within the same tumor can have different nutrient requirements and energy-producing strategies.
Some may depend heavily on glucose, while others can use fatty acids, amino acids, or other fuels.
This flexibility is one reason the phrase “starve cancer” is scientifically misleading.
Restricting one nutrient does not necessarily eliminate all energy sources available to a tumor.
Cancer cells can sometimes adapt by activating alternative metabolic pathways.
Fasting may nevertheless alter the overall environment in ways that make certain cancer cells more vulnerable to therapy.
Determining which tumors are metabolically sensitive is therefore an important area of current research.
Could Fasting Influence the Immune Response?
The immune system is another major area of investigation.
Preclinical studies suggest that fasting and fasting-mimicking diets can alter immune-cell metabolism, inflammatory signaling, and the composition of immune cells within the tumor microenvironment.
Some experiments have reported changes involving T cells, natural killer cells, macrophages, and other immune populations.
Researchers are particularly interested in whether metabolic interventions could complement immunotherapy by changing the conditions in which immune cells operate.
However, the relationship is not straightforward. Immune activation must be appropriately regulated, and different cancers have different immune environments.
Increasing an immune marker in a laboratory experiment does not necessarily translate into greater tumor destruction in a patient.
Human studies are therefore needed to determine which immune changes are clinically useful and whether they can improve responses to specific immunotherapies.
Fasting Is Not the Same as “Starving Cancer”
The expression “starve cancer” is popular online but does not accurately represent human physiology.
When someone stops eating, the body does not allow blood glucose to fall to zero.
Instead, it activates several mechanisms to maintain essential glucose levels.
The liver releases glucose from stored glycogen and later produces new glucose through gluconeogenesis. At the same time, fat breakdown increases and ketone bodies become a more important fuel.
A tumor therefore continues to exist within a metabolically regulated environment.
Fasting is better understood as a system-wide metabolic transition rather than a complete shutdown of cancer-cell nutrition.
Researchers are interested in whether this transition changes hormonal signaling, oxidative stress, nutrient availability, and treatment sensitivity.
This explanation is more scientifically accurate than claiming that fasting simply removes the food cancer needs.
Potential Positive Areas of Research
Despite the uncertainties, there are several reasons scientists continue to investigate fasting.
First, fasting can produce measurable changes in metabolic hormones such as insulin and IGF-1.
Second, laboratory experiments suggest that temporary nutrient restriction can influence tumor-cell stress responses and treatment sensitivity.
Third, selected human studies indicate that fasting-mimicking diets can be implemented during treatment when patients are carefully monitored.
Fourth, researchers have observed changes in immune and inflammatory pathways that could potentially interact with modern cancer therapies.
Another important concept is that dietary interventions may influence the context in which a drug works, rather than acting as a drug themselves.
In other words, fasting may eventually prove useful not because it independently eliminates cancer, but because a carefully timed metabolic intervention could potentially alter how a particular cancer responds to a particular treatment.
This possibility is one reason the field remains scientifically interesting.
What Are the Important Risks?
The potential risks deserve as much attention as the potential benefits.
Cancer patients may already be vulnerable to inadequate calorie and protein intake because of nausea, appetite loss, swallowing difficulties, taste changes, gastrointestinal symptoms, inflammation, or the effects of treatment.
Prolonged or poorly planned fasting can contribute to additional weight loss, muscle loss, dehydration, weakness, and nutritional deficiencies.
Loss of skeletal muscle is particularly important because muscle contributes to physical function and recovery.
A person undergoing intensive treatment may need adequate nutrition to maintain strength and tolerate therapy.
Therefore, an intervention that appears metabolically interesting could become harmful if it causes significant malnutrition.
This is why clinical studies generally use carefully defined protocols and monitor participants rather than simply telling patients to stop eating for several days.
Who Should Be Especially Careful?
Fasting should receive particular caution in people who are already underweight, experiencing unintended weight loss, losing muscle, struggling to eat enough, or dealing with significant treatment-related gastrointestinal problems.
People with diabetes also require special consideration because fasting can affect blood glucose and may interact with insulin or other glucose-lowering medications.
Individuals with kidney or other metabolic conditions may also require individualized medical advice.
A history of an eating disorder is another important consideration because restrictive dietary strategies can potentially trigger harmful patterns.
These issues demonstrate why there cannot be a universal fasting schedule for people with cancer.
A nutritional strategy that is tolerated by a relatively healthy patient with adequate body reserves may be inappropriate for a patient who is already nutritionally depleted.
Fasting During Chemotherapy Is Different From Fasting for General Health
Fasting for general metabolic health and fasting during cancer treatment are two very different situations.
A healthy person interested in time-restricted eating may be primarily concerned with body weight, glucose regulation, or general metabolic health.
A person undergoing chemotherapy has a completely different physiological situation.
Cancer treatment can influence appetite, blood counts, hydration, gastrointestinal function, energy requirements, and body composition.
Some treatments may increase nutritional demands, while others can make eating difficult.
Therefore, evidence from healthy adults cannot simply be transferred to patients receiving cancer therapy.
Likewise, evidence that intermittent fasting can help with weight management cannot be interpreted as evidence that fasting improves tumor response.
Oncology nutrition requires a broader assessment that considers the cancer, treatment, body composition, nutritional status, medications, and individual goals.
What Is a Fasting-Mimicking Diet?
A fasting-mimicking diet is designed to provide a limited amount of food while creating some of the metabolic conditions associated with fasting.
Rather than complete food deprivation, the person consumes a carefully structured low-calorie dietary pattern for a defined number of days.
Researchers are interested in this approach because complete fasting can be difficult to tolerate, particularly during cancer treatment.
An FMD may potentially provide some metabolic effects while supplying limited nutrients and calories.
Clinical trials have demonstrated that certain protocols can be implemented in selected patients under controlled conditions.
However, an important limitation is that fasting-mimicking diets are not all identical.
Calorie composition, macronutrient ratios, duration, timing, and formulation can differ.
Therefore, evidence for one studied protocol should not automatically be used to support every commercially available “fasting” product or diet.
The Role of Personalized Cancer Nutrition
The future of this field may move away from asking the broad question, “Does fasting work for cancer?” and toward a more precise question: Which patients might benefit from which metabolic intervention, at what time, and alongside which treatment?
Cancer medicine is increasingly becoming personalized according to tumor genetics, molecular characteristics, biomarkers, and treatment response.
Nutrition research may eventually follow a similar direction.
Researchers are investigating metabolic biomarkers, insulin and IGF-1 signaling, tumor characteristics, immune responses, body composition, and treatment type.
If future studies identify reliable predictors of benefit, metabolic interventions could potentially become one component of personalized supportive or therapeutic strategies.
However, that stage has not yet been reached.
At present, there is insufficient evidence to identify a universal fasting protocol that improves outcomes across cancer types.
Fasting, Ketogenic Diets, and Other Metabolic Strategies
Fasting is also part of a broader research field called metabolic oncology, which investigates how changes in nutrition and metabolism might interact with cancer biology.
Researchers have studied ketogenic diets, calorie restriction, fasting-mimicking diets, intermittent fasting, and specific nutrient-restricted approaches.
These interventions are related but should not be treated as identical.
A ketogenic diet generally emphasizes very low carbohydrate intake and higher fat intake, whereas fasting involves a period of reduced or absent food intake.
Some researchers are exploring whether combining metabolic interventions with radiation, chemotherapy, targeted therapy, or immunotherapy could create treatment-specific advantages.
At present, however, the evidence varies substantially by cancer type and intervention.
Interesting laboratory results should therefore be viewed as a reason for controlled clinical research rather than as evidence that every metabolic diet is beneficial during cancer treatment.
How Should We Interpret “Positive” Findings?
A major challenge in health communication is understanding what a positive research result actually means.
Suppose a study finds that fasting lowers IGF-1. That demonstrates a biological effect, but it does not automatically demonstrate improved survival.
Suppose another study reports a higher pathological response rate. That is more clinically relevant, but researchers still need to determine whether the effect persists in larger populations and whether it translates into improved long-term outcomes.
Similarly, changes in inflammatory markers or immune-cell populations can help researchers understand mechanisms but are not themselves proof of therapeutic success.
A useful evidence hierarchy therefore moves from laboratory observations to animal studies, early human feasibility studies, randomized clinical trials, systematic reviews, and ultimately consistent evidence showing meaningful patient outcomes.
Fasting research is currently progressing through these stages.
The Most Important Scientific Message
The most interesting aspect of fasting research is that it introduces the idea that cancer treatment may be influenced not only by the drug or radiation itself but also by the metabolic environment in which treatment occurs.
Cancer cells continuously respond to nutrients, hormones, oxygen, immune signals, and neighboring cells.
Fasting temporarily changes several of these factors at once.
This creates a scientifically plausible reason to investigate whether carefully timed metabolic interventions can modify treatment sensitivity.
At the same time, cancer cells are highly adaptable, and the response will probably not be identical across all tumors.
The current evidence therefore supports continued research rather than universal recommendations.